| |
| |
|
|
NextGen
Sciences was established in May 2000 by cofounders Dr Kevin
Auton, CEO, and David Wigley, Director of Operations, to address
the protein research market. It is expected that this market
will grow to $9 billion by 2009 (Frost and Sullivan, Front
Line Strategic Consulting). Since foundation, the company
has evolved to become a leading provider of integrated solutions
for protein research. |
| |
|
|
| |
|
|
|
NextGen
Sciences has successfully launched award winning technologies,
won over £0.75 million in grant awards, established
offices in Cambridgeshire, UK, and currently employs 35 people. |
| |
|
|
| |
|
|
|
The
company's first product was launched in 2002, The ProteinArray
Workstation, which is now marketed by PerkinElmer Life and
Analytical Sciences. The
unique technology is flexible, fully automated system for
processing multiple protein microarrays based on standard
microscope slide formats. |
| |
|
|
| |
|
The
second technology to be launched by NextGen Sciences in 2003
was the expressionfactory, which is the first commercially
available technology to fully automate protein expression,
from gene to protein. Following the activation of a gene,
gene fragment or domain using Invitrogen’s Gateway technology,
the advanced system expresses each gene in parallel, in multiple
vectors. Uniquely, the expressionfactory also grows each of
the newly created cell lines in parallel, before purifying
all of the different versions of each protein. This is achieved
without user supervision or intervention. |
| |
| |
|
|
|
|
| |
|
|
|
The
expressionfactory allows a matrix approach for the cloning
and expression of any gene, increasing the chances of successfully
isolating useful protein. |
| |
|
|
|
|
| |
|
|
|
In
2002, NextGen Sciences won a LINK Applied Genomics award to
fund a three-way initiative with the University of Cambridge
and Cytomyx. The three year programme of work is focusing
on the creation of protein biochips for diagnosis of breast
cancer. The research is progressing well and it is hoped that
these chips will be used globally by researchers in the field.
|
| |
|
|
|
|
| |
|
 |
|
In
2002, NextGen Sciences won a LINK Applied Genomics award. |
| |
|
|
|
|
| |
|
|
|
2005
was a pivotal year for NextGen Sciences. The original CEO
Dr Kevin Auton left the company and was replaced by Dr James
Heffernan. Following a strategic review the company launched
a number of new products including the baculoworkstation;
contractexpress and the first expressionworkstation was successfully
demonstrated to customers. The company achieved public status
by listing on the UK AIM market as of 30th Dec. |
| |
|
|
| |
|
top
of page |
|
|
|
|
